Measuring Patient-Centered Outcomes in the Pfizer-CCTG Trial of Azithromycin vs. Rifabutin vs. Both for the Prevention of HIV-Associated Mycobacterium avium

Instruments, Methods, Application, and Results

by Samuel A. Bozzette, Sandra H. Berry, Brian C. Wright, David E. Kanouse, Naihua Duan, Carol A. Edwards

Download eBook for Free

FormatFile SizeNotes
PDF file 2.3 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

The authors assess health-status outcomes of prophylaxis for Mycobacterium avium bacteremia in patients with advanced HIV disease. This report summaries the developmental work performed for trials, the field experience, and associated findings.

Research conducted by

This report is part of the RAND Corporation draft series. The unrestricted draft was a product of the RAND Corporation from 1993 to 2003 that represented preliminary or prepublication versions of other more formal RAND products for distribution to appropriate external audiences. The draft could be considered similar to an academic discussion paper. Although unrestricted drafts had been approved for circulation, they were not usually formally edited or peer reviewed.

Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.